Physician profile
Benjamin Huang
NPI 1508122516
$22,571.53
in general payments reported to CMS, 2019-2025
23 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.03 · 2020: $33.62 · 2021: $11.77 · 2022: $13K · 2023: $7,585 · 2024: $1,276 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,650 · Food and Beverage: $2,721 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $525 · Education: $14.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,650.00 |
| Food and Beverage | $2,721.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $525.00 |
| Education | $14.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $18,814.28 | 2022-2024 | |
| Fresenius USA Marketing, INC. | $407.52 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $406.79 | 2022-2025 | |
| Travere Therapeutics, INC. | $384.89 | 2024-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $375.38 | 2022-2025 | Farxiga, Lokelma |
| Amgen INC. | $336.85 | 2022-2025 | Tavneos, Krystexxa, Parsabiv |
| Horizon Therapeutics Plc | $336.44 | 2022-2023 | Krystexxa |
| Vifor Pharma, INC. | $251.04 | 2022-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $250.35 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $207.65 | 2025 | Ozempic, Wegovy, Rybelsus |
| Melinta Therapeutics, LLC | $125.00 | 2023 | Kimyrsa |
| Grt US Holding, INC. | $125.00 | 2022 | |
| Medtronic, INC. | $103.34 | 2023 | Hawkone |
| Opko Pharmaceuticals, LLC | $99.75 | 2021-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $95.87 | 2022-2025 | Ultomiris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.06 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $52.63 | 2024-2025 | |
| Akebia Therapeutics INC | $34.55 | 2022-2024 | Vafseo |
| Xeris Pharmaceuticals, INC. | $17.36 | 2025 | Keveyis |
| Lilly USA, LLC | $16.69 | 2023 | Jardiance |
| Apellis Pharmaceuticals, INC. | $15.19 | 2025 | |
| Grifols USA, LLC | $15.00 | 2020 | |
| Gilead Sciences, INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.